FDA Oversight Of Medical Products Remains A "High-Risk" Concern For GAO
This article was originally published in The Gray Sheet
Executive Summary
The Government Accountability Office is once again listing FDA's ability to ensure the safety and effectiveness of devices, drugs and other medical products on its roster of "high-risk" concerns.
You may also be interested in...
Regulatory News In Brief
FDA issues draft-guidance on accreditation of third-party reviewers for 510(k)s and final guidance for surgical ablation devices. More regulatory news.
FDA Long-Term Globalization Strategy Under Development
Coping with an increasingly global device and drug industry will require a paradigm shift that relies less on FDA's own staff and more on data and resource sharing with other countries, the agency says.
GAO “High-Risk List” Urges Enhanced FDA Oversight Of Medical Products
The Government Accountability Office added enhanced oversight of devices, drugs and other medical products to its list of "high-risk" priorities in a report to Congress released Jan. 22